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ABSTRACT
Few data are available on the prevalence of advance care planning (ACP) in patients undergoing hematopoietic
cell transplantation (HCT). We surveyed adult patients pre-HCT to ascertain completion of various elements
of ACP. We also reviewed medical records for documentation of discussions regarding ACP and for the
presence of written advance directives. Evaluable surveys were returned by 155 of 335 patients (46%) who
underwent HCT during the study period; we obtained permission for medical record review from 137 of these
155 survey respondents (88%). We found that 69% of the respondents reported having designated a health care
proxy, 44% had completed a living will, 61% had prepared an estate will, and 63% had discussed their wishes
regarding life support with family and friends. In contrast, only 16% had discussed their wishes regarding life
support with their clinicians. Documentation of discussions between clinicians and patients regarding most
elements of ACP was rare. Written advance directives were present in the charts of 54 patients (39%). ACP was
more common in older, college-educated, and allogeneic transplant patients. Even though ACP was more
prevalent among this sample than in the general population, its use still could be enhanced, given the high risks
of decisional incapacity and death that HCT patients face.
© 2007 American Society for Blood and Marrow Transplantation
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Hematopoietic cell transplantation (HCT) is a
herapeutic option for patients with various life-
hreatening malignant and nonmalignant disorders
f the lymphohematopoietic system. For many such
onditions, HCT offers the only possibility of long-
erm survival. However, HCT involves high risks
f short- and intermediate-term mortality and mor-
idity, primarily from direct toxic effects of con-
itioning regimens, infectious complications, and
cute and chronic graft-versus-host disease (GVHD). In
dults undergoing HCT, mortality within the ﬁrst
00 days after transplantation varies from 7% to
7%, depending on clinical and other factors [1].
ortality from recurrence of underlying disease is
lso high.
Given the substantial risks of life-threatening ihort- and intermediate-term complications, advance
are planning (ACP) is especially relevant for patients
onsidering HCT [2]. Elements of ACP might include
esignation of a health care proxy, completion of a
iving will, preparation of an estate will, and conver-
ations with loved ones and health care providers
bout the patient’s wishes in various circumstances.
eyond the substantial risks from both underlying
isease and its treatment, several factors might be
xpected to foster high levels of ACP in patients con-
idering HCT. These include the elective nature of
he procedure (typically, weeks to months elapse be-
ween initial consideration of and admission for
CT); the predictability of potentially fatal post-
CT complications, which are generally associated
ith loss of decision making capacity due to critical
llness; and the fact that many patients undergoing
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S. Joffe et al.66CT have lived with life-threatening illness for
onths or years.
Despite these grounds for advocating ACP before
CT, some patients might prefer not to undertake
reparations for or discuss end-of-life contingencies.
n particular, for most patients considering HCT, the
rocedure represents a last hope for long-term sur-
ival. Patients who decide to undergo the procedure
ay have strong psychological motivations to avoid
welling on the substantial risks. In addition, living
ills are problematic instruments for extending pa-
ients’ autonomy to times of decision making incapac-
ty, although their deﬁciencies are mitigated some-
hat when complications are predictable [3].
urthermore, patients and clinicians might not view
ormal designation of a health care proxy as essential if
patient’s preferred proxy (eg, spouse) already re-
eives priority under state laws regarding surrogate
ecision making for medical care. Similarly, patients
ay view estate wills as superﬂuous if their wishes
egarding distribution of assets are consistent with
tate intestacy laws, which establish rules for distrib-
ting the assets of individuals who die without valid
ills.
Few systematic data are available regarding ACP
n patients undergoing HCT [4]. Consequently, we
xplored the prevalence and correlates of ACP as
eﬁned both by self-report and by review of documen-
ation available in hospital charts.
ETHODS
tudy Population
The data presented here derive from a longitudi-
al quality-of-life survey study in adult patients un-
ergoing HCT in the Dana-Farber Cancer Institute/
righam and Women’s Hospital (DFCI/BWH)
rogram. All patients who underwent transplantation
etween July 30, 2001 and June 3, 2003 (n  335)
ere eligible for inclusion in this analysis. (Accrual
as interrupted between August 2, 2002 and February
0, 2003, however, to permit recruitment for a sepa-
ate pilot study of psychosocial screening [5].)
We characterized disease status at the time of
tudy enrollment into 3 prognostic groups based on
isk of death by 1 year. Good-risk patients were those
ith acute leukemia in ﬁrst complete remission, sta-
le-phase chronic myeloid leukemia, early myelodys-
lastic syndrome (ie, refractory anemia with or with-
ut ringed sideroblasts), or aplastic anemia. Poor-risk
atients were those in relapse or with refractory dis-
ase. All other patients were considered intermediate
isk.
Patients considering HCT were generally seen by
single attending physician during their evaluationnd preparation for transplantation. Evaluation by a tocial worker was variable and sometimes occurred
nly after a patient was admitted for HCT unless a
hysician or nurse raised psychosocial concerns. Be-
ore or at the time of their ﬁrst visit, patients received
binder with general information about HCT, which
ncluded a section on ACP.
The speciﬁc conditioning regimen and graft ma-
ipulation, if any, was according to protocol require-
ents or physician and patient preference. Condition-
ng regimens typically involved cyclophosphamide,
armustine, and etoposide for autologous transplants
or lymphoma; melphalan for multiple myeloma; total
ody irradiation plus cyclophosphamide for myeloab-
ative allogeneic transplants; and ﬂudarabine plus
usulfan for nonmyeloblative allogeneic transplants.
VHD prophylaxis typically involved either T-cell
epletion or calcineurin inhibitors, with additional
gents (eg, steroids, mycophenolate, sirolimus, meth-
trexate) determined by protocol requirements. De-
ails of the transplantation regimens and GVHD pro-
hylaxis are described elsewhere [6-10].
urvey Methods
The study was approved by the DFCI Institutional
eview Board (IRB). Surveys, along with self-ad-
ressed stamped return envelopes, were included in
linical information packets mailed to patients after
he decision was made to proceed with HCT but
efore hospital admission for transplantation. These
ackets also contained patient schedules and informa-
ion about the admission process and the hospital, but
id not contain information about ACP. As approved
y the IRB, return of the survey constituted evidence
f informed consent; there were no explicit consent
iscussions regarding this study between physicians or
tudy staff and eligible patients.
A total of 160 patients (48%) returned the survey.
f these, 5 were inevaluable due to missing responses
o all 5 questions related to ACP. Thus, of the 335
atients who underwent transplantation during the
tudy period, 155 (46%) were included in the present
nalysis.
urvey Instrument
The survey instrument is a 189-item questionnaire
ddressing quality of life, functional status, mental and
hysical health, expectations about prognosis and tox-
city, treatment decision making, steps taken to pre-
are for transplantation, and demographic informa-
ion. Data from an earlier version of the survey, along
ith a description of its development, have been pub-
ished previously [11,12].
The major survey-based outcome variables for the
resent analysis were patients’ responses to 5 ques-
ions about preparation for HCT:
12
3
4
5
t
s
d
i
t
M
t
t
s
p
n
t
1
f
s
m
s
w
r
t
i
h
c
o
f
p
b
i
h
d
m
p
r
ﬁ
r
c
c
c
w
c
e
r
p
r
t
t
p
a
a
i
n
n
S
s
p
A
a
d
d
i
t
a
t
p
0
c
r
b
n
a
p
r
a
s
i
p
t
a
m
i
p
F
O
O
a
U
r
w
.
e
c
d
e
s
h
Advance Care Planning in Hematopoietic Cell Transplantation 67. Have you designated a health care proxy (someone
to make medical decisions on your behalf)?
. Have you prepared a will?
. Have you completed a living will?
. Have you discussed your wishes regarding life sup-
port with your family or friends?
. Have you discussed your wishes regarding life sup-
port with your doctor or nurse?
Completion of these 5 actions was rated as impor-
ant by more than 70% of participants in a national
urvey on end-of-life care [13] and provides objective
ata on behavioral preparations for life-threatening
llness. Response options included “no,” “no, but plan
o,” and “yes.”
edical Records Review
For the present analysis, we sought separate writ-
en consent from living survey respondents to review
heir hospital charts. The IRB did not require permis-
ion from next-of-kin to review charts of deceased
atients. Eighteen survey respondents denied or did
ot respond to our request for permission to review
heir medical records; thus, we reviewed the records of
37 respondents (88%).
We developed a standardized abstraction form to
acilitate systematic chart review. Charts were ab-
tracted by a trained research assistant, with key ele-
ents related to ACP (eg, documentation of discus-
ions between clinicians and patients, presence of
ritten advance directives) reabstracted by a second
esearch assistant to increase sensitivity. Because pa-
ients received their outpatient care at DFCI and their
npatient care at BWH, we abstracted both clinic and
ospital charts for each patient. Review of the clinic
hart encompassed all physician, nurse, and psychos-
cial visits occurring during the 4-month period be-
ore the date of admission for transplantation. If a
atient had fewer than 3 visits during the 4 months
efore admission, the review period was extended to
nclude at least 3 visits, if possible. Review of the
ospital chart encompassed attending physician, resi-
ent, fellow, nursing, and psychosocial clinician ad-
itting notes only; later notes during the index hos-
italization or during subsequent admissions were not
eviewed. Relevant discussions were noted and classi-
ed as addressing 1 or more of 8 prespeciﬁed subjects
elated to ACP (possibility of dying from transplant
omplications, possibility of losing decision making
apacity, wishes if seriously ill and incapacitated, dis-
ussion with family or friends about patient’s wishes,
ho should speak for the patient if incapacitated,
ompletion of an advance directive, completion of an
state will, and do-not-resuscitate orders). We also
ecorded the presence of written advance directives in
atients’ charts. DFCI policy in force at the time
equired that copies of advance directives be placed in che medical record, but did not require documenta-
ion of discussions regarding ACP. In contrast, BWH
olicy required that attending physicians, house staff,
nd admitting nurses explain to patients the purpose
nd uses of advance directives and document the ex-
stence and substance of advance directives and the
ature of patients’ wishes in the hospital admission
otes.
tatistical Analysis
Using descriptive statistics, we report patients’
urvey responses regarding ACP, the proportions of
atients with documentation of discussions about
CP in the outpatient and inpatient medical records,
nd the proportion of patients with written advance
irectives in their medical records. To examine pre-
ictors of the intensity of ACP, we created a compos-
te dependent variable by summing the responses to
he 5 survey questions about ACP. For each question,
“no” response was assigned 0 points, “no, but plan
o” was assigned 1 point, and “yes” was assigned 2
oints. The resulting summary score could range from
(no elements of ACP completed) to 10 (all elements
ompleted). This summary scale had high internal
eliability (Cronbach’s   0.76). Because of the am-
iguity of “no, but plan to,” we also created an alter-
ative composite score in which this response was
ssigned 0 points. Results using this alternative end-
oint were similar and are not reported here.
We constructed an ordinary least squares linear
egression model that included demographic, clinical,
nd other variables as candidate predictors of the ACP
ummary score. Variables included in the initial model
ncluded age, sex, college education, marital status,
resence of children, income, transplant risk group,
ype of transplant (allogeneic vs autologous), patients’
nd physicians’ estimates of 1-year treatment-related
ortality (from the patient survey and an accompany-
ng physician survey) [11], mental and physical com-
osite score from the Medical Outcomes Study Short-
orm 12 (SF12) [14], and Eastern Cooperative
ncology Group (ECOG) performance status [15].
rdinal independent variables were dichotomized at
s close to the sample median as permitted by the data.
sing backward stepwise elimination, we sequentially
emoved from the model independent variables that
ere not associated with the summary score at P 
05. Because we viewed the analysis as hypothesis-gen-
rating, we did not adjust for multiple comparisons.
In our second analysis, we examined factors asso-
iated with the presence of an advance-care directive,
ated on or before the date of transplantation, in
ither the clinic or hospital chart. A patient was con-
idered to have an advance directive if we found a
ealth care proxy form, a living will, or both in the
hart. We constructed a logistic regression model that
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S. Joffe et al.68ncluded the candidate predictor variables listed ear-
ier, then sequentially eliminated variables from the
odel that did not achieve P  .05. As before, we
ade no adjustment for multiple comparisons.
All analyses were conducted using Stata 8 software
Stata Corp, College Station, TX).
ESULTS
tudy Participants
Table 1 lists demographic and clinical character-
stics of the survey respondents and nonrespondents.
he mean age was 48.5 years, and almost half were
emale. Most were white, college-educated, married
r living as married, had household incomes of at least
50,000 per year, and had at least 1 child. Clinically,
ost were undergoing allogeneic transplantation,
ere in the intermediate-risk group, and were symp-
omatic from their disease or its treatment. Respon-
ents completed surveys a median of 20 days before
he date of HCT.
Nonrespondents and respondents were of similar
ge and sex, but nonrespondents were more likely to
able 1. Demographic and Clinical Characteristics of Respondents (n 
Characteristic
ge at transplantation, mean (SD)
emale
onwhite race
arried/living as married†
ollege degree
ousehold income >$50,000/year
as at least 1 child
llogeneic transplant
isk group
Low
Intermediate
High
ymptomatic (ECOG performance status >1)
ays between survey completion and HCT, median (IQR)
D, standard deviation; N/A, not available; IQR, interquartile rang
Includes African-American (n  3), Hispanic/Latino (n  1), and
Data on marital status, education, income, number of children, an
not return the baseline survey and could not be obtained by ot
able 2. Self-Report of ACP Among Patients Undergoing HCT (n15
Have You...*†
esignated a health care proxy (someone to make medical decis
your behalf)?
iscussed your wishes regarding life support with your family or
repared a will?
ompleted a living will?
iscussed your wishes regarding life support with your doctor or
“Please tell us if you have done any of the following in preparatio
Totals may not add to 155 due to missing responses to individual questie nonwhite (11% vs 3%; P  .006). Nonrespondents
ere slightly more likely than respondents to be in the
igh-risk group and to be undergoing autologous
ather than allogeneic transplantation, though these
ifferences did not achieve statistical signiﬁcance. Re-
pondents and nonrespondents had similar survival
xperiences (P  .65; log-rank test).
elf-Report of ACP
Most respondents (69%) reported having desig-
ated a health care proxy, and 61% reported having
repared an estate will (Table 2). Fewer (44%) re-
orted having completed a living will. Of the 148
atients for whom data were available, 28% had nei-
her a health care proxy nor a living will. Although
ost (63%) reported having discussed their wishes
egarding life support with family or friends before
dmission for HCT, only 16% reported having dis-
ussed these wishes with their doctor or nurse. Among
hose who had not discussed their wishes with their
octor or nurse, only 42% reported planning to do so.
The mean ACP score among respondents was 5.9
standard deviation,  3.0; range, 0–10). Older age,
espondents Nonrespondents
P Valueer Percent Number Percent
1.8) 46.5 (12.0) .12
43% 73 41% .71
* 3% 20 11% .006
77% N/A –
58% N/A –
67% N/A –
81% N/A –
70% 110 61% .09
15% 17 9% .07
70% 122 68%
15% 41 23%
65% N/A –
-34) N/A –
American (n  1) patients.
eported performance status were not available for patients who did
ans.
Yes No, But Plan to No
Number (Percent) Number (Percent) Number (Percent)
106 (69) 20 (13) 27 (18)
? 98 (63) 25 (16) 32 (21)
94 (61) 12 (8) 49 (32)
66 (44) 16 (11) 69 (46)
24 (16) 54 (35) 76 (49)
our transplant.”155)
R
Numb
48.5 (1
66
5
119
90
100
126
109
24
108
23
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Advance Care Planning in Hematopoietic Cell Transplantation 69ollege education, and allogeneic transplantation were
ssociated with greater intensity of ACP in the mul-
ivariate model (Table 3). These 3 factors jointly ex-
lained more than 1/4 of the variance in ACP scores
R2 .28; model P .0001). The association between
ge and most elements of ACP was especially strong
Figure 1).
ocumentation of ACP in the Medical Record
Among the 8 elements of ACP that we abstracted
rom patients’ medical records, discussions about the
ossibility of dying from transplantation-related com-
lications were documented in either the clinic or the
able 3. Correlates of Self-Reported ACP and a Pretransplantation Ad
Patient Characteristic
Self-Reported ACP S
Increment‡
95% Confiden
Interval
ge, per decade 1.2 0.9-1.6
ollege education 1.1 0.3-2.0
llogeneic transplantation 1.3 0.3-2.2
Independent variables that were not signiﬁcantly associated with h
sex, marital status, presence of children, household income great
likelihood of treatment-related mortality (TRM), physician est
score of the SF12, and ECOG performance status. R2 of the ﬁn
Independent variables that were not signiﬁcantly associated with pr
regression model included sex, college education, marital status,
type of transplant, transplantation risk group, patient estimate o
of the SF12, physical composite score of the SF12, and ECOG
Absolute increment in planning score (ie, beta coefﬁcient) associa
igure 1. Completion of elements of ACP, by age group. A, desig
ompleting an estate will; D, completing a living will; E, discussing
vailable in clinic or inpatient chart. P values are computed using Wilcoxoospital charts of 82 patients (60%), and discussions
bout advance directives were documented in the
harts of 61 patients (45%) (Table 4). In 45/61 cases,
ocumentation of discussions about advance directives
as limited to completion of relevant ﬁelds in the
reprinted inpatient nursing intake form. Docu-
entation regarding do-not-resuscitate orders was
resent in the charts of 25 patients (18%); in 22 of
5 cases, this documentation was limited to a state-
ent about “code status” in the resident’s admission
ote. Documentation of discussions about each of
he other 5 elements of ACP was present in  6%
f charts.
irective in the Hospital Chart Inpatients Undergoing HCT
Pretransplantation Advance Directive
Available in the Hospital Chart†
P Value Odds Ratio
95% Confidence
Interval P Value
<.001 1.9 1.3-2.7 <.001
.01 —
.008 —
lanning scores at P  .05 in the linear regression model included
the sample median, transplantation risk group, patient estimate of
f TRM, mental composite score of the SF12, physical composite
el  0.28.
of an advance directive in the hospital chart at P .05 in the logistic
ce of children, household income greater than the sample median,
ood of TRM, physician estimate of TRM, mental composite score
mance status.
h a 1-unit increase in the independent variable.
a health care proxy; B, discussing one’s wishes with loved ones; C,
ishes with physician or nurse; F, copy of written advance directivevance D
core*
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igher p
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S. Joffe et al.70We identiﬁed a written advance directive (ie,
ealth care proxy and/or living will) in the clinic or
ospital chart of 54 patients (39%). Advance directives
ere completed a median of 116 days (interquartile
ange, 12-522 days) before the date of transplantation.
n the logistic regression model, older patients were
ore likely to have an advance directive in the medical
ecord (Table 3); patients under age 40 rarely had an
dvance directive (Figure 1).
We noted a statistically signiﬁcant but imperfect
ssociation between self-report of a health care proxy
r living will and presence of an advance directive in
he chart. Of the 104 patients who reported designat-
ng a proxy or completing a living will, 50 (48%) had
n advance directive in the chart, compared with 4 of
he 33 patients (12%) who reported not having com-
leted a proxy or living will (P  .001).
ISCUSSION
Several notable ﬁndings emerged from our analy-
is of self-reported and documented ACP among adult
atients undergoing HCT. First, even though many
atients reported having engaged in various aspects of
CP, including designating a proxy, discussing their
ishes with loved ones, and completing an estate will,
substantial minority had not taken these steps. Sec-
nd, patient-reported and documented discussions be-
ween patients and clinicians about most elements of
CP were rare [16]. Third, although a sizeable mi-
ority of patients had written advance directives avail-
ble in their hospital charts, most did not. Finally,
ounger patients—especially those under age 40—
ere much less likely than older patients to have
ngaged in ACP. Other factors that might be expected
o predict completion of ACP, such as being married,
able 4. Prevalence of Advance Care Discussions and Written Advance
dical Record (n  137)
Documentation of Discussion*
ossibility of dying from transplantation-related complications
ompletion of an advance directive
o-not-resuscitate order
erson who should speak for the patient if incapacitated
iscussion with family or friends about patient’s wishes if incapac
atient’s wishes if seriously ill and incapacitated
ossibility of losing decision-making capacity
ompletion of an estate will
ritten advance directive present§
Any advance directive
Health care proxy or durable power of attorney
Living will
Discussion documented, or written advance directive located, in e
45 of 61 instances of documentation about advance directives reﬂe
forms.
22 of 25 notes describing do-not-resuscitate status were resident
Limited to advance directives completed on or before the date ofaving children, disease risk group, perceived mortal- wty risk, and performance status or physical function-
ng before HCT, were not associated with ACP.
Rates of completion of written advance directives
bserved in the present cohort are higher than those
ound in most other studies, although few data from
nalogous settings involving seriously ill patients un-
ergoing high-risk elective procedures are available
17]. Many studies have documented limited use of
CP in various populations, despite the fact that most
atients say that they desire advance directives [18]. In
he Study to Understand Prognoses and Preferences
or Outcomes and Risks of Treatment (SUPPORT),
hich enrolled patients with a median predicted life
xpectancy of 6 months, 20%–24% of patients had
dvance directives at the time of the index hospital-
zation [19]. The prevalence of advance directives var-
es across studies, although most demonstrate comple-
ion rates comparable to or lower than those observed
n SUPPORT [16,18,20-29]. Several studies suggest
hat the prevalence of advance directives may be
igher in patients with cancer than in other groups
20,24,30,31]. Completion of advance directives and
ther elements of ACP also varies by race and ethnic-
ty [25,29,30,32]. With few exceptions [28], interven-
ions to increase the use of advance directives have
hown limited success [33,34].
The data presented here suggest that many pa-
ients considering HCT neither discuss nor plan to
iscuss end-of-life contingencies with their clinical
eam. This ﬁnding might be expected if frank discus-
ion of end-of-life contingencies threatened the hope
or cure that many patients invest in HCT [11].
mong respondents who had not discussed their
ishes regarding life support with their physician or
urse, most reported no plans to do so. It is unclear
rom these data what proportion of these patients
ves Among Patients Planning to Undergo HCT, as Documented in the
Number Percent
82 60%
61† 45%
25‡ 18%
8 6%
5 4%
3 2%
0 0%
0 0%
54 39%
54 39%
30 22%
inic (DFCI) or inpatient (BWH) chart.
mpletion of relevant ﬁelds in the preprinted nursing hospital intake
l admitting notes documenting the patient’s “code status.”Directi
itated
ither cl
cted co
hospitaould welcome such conversations if initiated by cli-
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Advance Care Planning in Hematopoietic Cell Transplantation 71icians and what proportion would prefer that no such
onversations take place. Data from other studies sug-
est that some patients with serious illness do not wish
o discuss ACP with their physicians [31,32,35]. Nev-
rtheless, given that approximately 40% of patients
ill die within 1 year of HCT, clinicians arguably
hould routinely offer to discuss the subject, to meet
he needs of patients who welcome such conversations
ut hesitate to initiate them [18,36].
In considering our ﬁndings, it is necessary to ac-
nowledge the existence of skepticism about the
ffectiveness of ACP at achieving its intended aims.
here is limited evidence that advance directives
ubstantially alter the course of end-of-life care
20,37-39], although some studies suggest improved
sychological outcomes in survivors with whom pa-
ients previously discussed their end-of-life prefer-
nces [20,40]. Proxies have also been found to be poor
udges of patients’ preferences regarding end-of-life
ecisions, although this ﬁnding may simply highlight
he need for more explicit discussion between patients
nd proxies [30,41-44]. Consequently, Fagerlin and
chneider recently argued that living wills have not
ulﬁlled their promise of “extend[ing] patients’ exer-
ise of autonomy beyond their span of competence”
3]. Despite these caveats, however, there is general
greement that a comprehensive approach to ACP,
ncluding the use of written advance directives as well
s conversations between patients and their loved ones
nd clinicians, is an integral part of high-quality care
or patients with life-threatening illness [45].
It is important to explicitly address the objection
hat formal designation of a health care proxy may be
uperﬂuous when state law regarding the priority of
urrogate decision makers is consistent with patients’
ishes. If this were the case, then we might expect
iscussions of ACP or completion of advance direc-
ives to be more common in unmarried patients, for
hom the appropriate proxy is less clear, than in
arried patients. That we observed no such a differ-
nce argues against such targeting of ACP.
Our study has several limitations. First, the data
haracterize the experience of a single institution and
ay not reﬂect practices in other settings. For exam-
le, the average socioeconomic status (SES) of pa-
ients treated in the DFCI/BWH program is high;
verall rates of ACP completion might be even lower
n other populations that include more patients with
ow SES. Also, because Massachusetts does not grant
tatutory recognition to living wills, their use by pa-
ients in our cohort may be more limited than would
e observed in other regions. However, within our
ohort, Massachusetts residents were no less likely
han residents of other states to complete living wills
data not shown). Second, the response rate to the
urvey was lower than we would have liked, even
hough respondents were generally similar to nonre-pondents with respect to measured characteristics. In
ddition, there is no reason to suspect that the major
ssociations that we observed—particularly the strong
elationship between young age and lack of ACP—
hould differ in patients who did not respond. Third,
he limited evidence of discussions regarding ACP
ound in patients’ charts may reﬂect a lack of docu-
entation rather than of actual discussion [16]. Fi-
ally, the survey question regarding designation of a
ealth care proxy did not clearly distinguish between
nformal and written assignment, although responses
o this question did strongly predict the presence of a
ritten advance directive in the medical chart.
In conclusion, despite the many reasons favoring
CP among patients undergoing HCT, there is room
or increased attention by both patients and clinicians to
his issue. The lack of ACP is especially striking in
ounger patients. Whether missed opportunities for
CP are due to clinicians’ reluctance to raise the subject
r to patients’ preferences not to engage in these con-
ersations or perform the relevant actions remains un-
lear. More studies are needed to examine whether our
bservations generalize to other settings, to clarify the
actors responsible for the underuse of ACP in HCT,
nd to correlate ACP with important outcomes. Finally,
lthough interventions that successfully boost rates of
CP in the medical setting are elusive, our ﬁndings
uggest the importance of renewed efforts to identify
uch interventions, particularly for patients undergoing
igh-risk procedures such as HCT.
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